Alumis' Phase 3 Trial Results for Envudeucitinib Show Significant Efficacy

AI Summary

Alumis announced results from a Phase 3 trial of envudeucitinib for psoriasis indicating a significant percentage of participants achieved the primary endpoint. Specific efficacy rates were reported at 70% for the treatment group compared to 30% for the placebo group. The trial included over 300 participants, which supports further developments and potential regulatory submission. These results could impact Alumis' stock performance positively as they advance towards commercialization.